A venture caputal firm was founded in 1996 and has offices in Palo Alto, CA, Shanghai, Beijing, Hongkong, Taipei. The firm is currently making investments in early-stage healthcare companies from one of its funds. The firm invests exclusively in the healthcare sector; the firm invests primarily in the USA and Greater China but will also invest in other regions such as Europe and ASEAN countries. Within China, the firm makes growth investments in companies but also find some companies with interesting and innovative product in recent years there; in the USA and other regions, the firm makes both venture and growth-equity stage investments in both pre-revenue and revenue-stage companies. The firm’s allocations are highly varied. The firm makes investments of typically $5-20 million. The firm is open to syndication. The firm is also particularly interested in working with companies that are open to or actively interested in seeking partnerships or opportunities in China.

The firm invests in therapeutics, medical devices, diagnostics, healthcare services, and clinically-oriented healthcare IT, and will consider investing in any indication area or technology subsector; however, orphan indications, dermatology/aesthetics, oncology, gene therapy, cell therapy, are of particular interest in the biopharma space; general surgery, neurovascular, cardiovascular, minimally invasive technologies, women’s health, respiratory care, novel diagnostics and orthopedics are of particular interest in the device space. Healthcare AI is an area we are interested and exploring. For devices and diagnostics, the firm only invests in commercial-stage companies. Generally, the firm does not invest in imaging.

The firm is flexible regarding management teams and works with both serial entrepreneurs and entrepreneurs who lack industry experience. In addition to investing in private companies, the firm is able to invest in public companies by means of PIPEs or public market placements. The firm is interested in investing in companies with products that can demonstrate cost-effectiveness.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A venture arm of the world’s leading provider of products and services for people with chronic kidney failure is headquartered in Germany. The firm has offices in USA, Germany, and Israel, and is actively seeking early-stage investment opportunities that align with Fresenius’ core businesses. Typical size of investment is around $5M, and the firm focuses on Series A to B rounds. The firm is open to global opportunities.

The firm is interested in products and technologies across therapeutics, medical devices, diagnostics, and digital health that target the following therapeutic sectors: chronic kidney disease and dialysis, intensive care medicine, cardiovascular diseases, autoimmune diseases, diabetes, and other kidney-related diseases. In terms of medical devices, the firm is open to 510k and PMA regulatory pathways.

The firm is open to working with all types of management teams. The firm can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

An investment firm based in the USA is interested in therapeutics companies that are 12-18 months from IND, although the firm may consider earlier-stage companies which are first in class. The firm invests in assets that have global opportunities with ticket size from $0.5-20M, depending on the opportunity and stage of the asset. The firm is actively involved in-licensing novel first in class assets.

Within therapeutics, the firm is agnostic to modality and indication. The firm does tend to invest more in oncology and regenerative medicine, but more due to a larger amount of deal flow in these areas.

The firm is an active investor, and will take a board seat in all of their portfolio companies. While they prefer to lead, the firm will co-invest with other partners. The firm makes use of their deep drug development expertise to advance their portfolio companies toward clinic.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in USA with additional offices in China invests in early-stage life science ventures, from Seed to Series B, with Series A and Series B being the firm’s sweet spot. Typical size of investment ranges from $1-2M in seed stage companies, and $3-5M in venture round companies.
The firm also has an advisory service that supports entrepreneurs to expand to the Chinese market, and the firm has multiple offices in China and needed expertise to support the entrepreneur’s vision.

Currently, the firm is most interested in companies based in USA, Israel, and Western Europe, particularly companies in the Nordic region.

The firm will consider therapeutics, medical devices, diagnostics, and life science tools. The firm is most interested in medical devices, and their interests include medtech and biotech combination products, novel methods of drug delivery, in vitro diagnostics (novel instruments and reagents), etc. The firm is interested in both 510K and PMA devices. Within therapeutics, the firm is more interested in clinical assets and typically do not look at pre-clinical companies unless the opportunity is compelling. Current main indication areas of interest for the firm are cardiovascular disease, oncology, and women’s health.

The firm seeks to work with management teams who are passionate about their technology and dedicated to creating values for the larger community. Though the firm is able to support companies who are interested in entering the China market, having a China angle is not necessary for investment. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in USA looks to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers company that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.

The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences venture capital fund based in Hong Kong currently manages three funds and is actively seeking investment opportunities. On average, the size of investment is $5-25M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.

The firm is focused on Therapeutics and Medical Devices opportunities. The firm’s core focused therapeutic areas include oncology, immunology, metabolic and CNS diseases, but is also focused on new modalities and platform technologies. The firm is also interested in interventional, novel medical devices in cardiovascular, neuro-vascular diseases.

The firm prefers management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The life science investment arm of a global private equity firm with multi-billion dollars in assets under management has offices across the USA. The fund may invest a total of up to $20 million per portfolio company across multiple financing rounds, and may be a lead investor or a co-investor. The firm is interested in life science opportunities worldwide. The PE firm also has a separate investment arm that invests in early growth companies in the medical device, healthcare IT and diagnostics sectors.

The firm invests in therapeutics, medical devices and diagnostics. For therapeutic investments, the fund generally looks for clinical proof of efficacy in Phase Ib or IIa trials. For PMA medical devices, the firm also requires clinical proof of efficacy data. For 510k devices and diagnostics, the firm makes growth equity investments in companies that have approved products and are in early commercialization. It is required that diagnostics have reimbursement codes. The firm will consider investments in any indication or technology area.

The growth-stage investment arm invests in digital health, medtech and diagnostics companies with revenue streams, and uses a variety of structures to provide credit or royalty financing to early growth stage companies.

The firm invests in both experienced management teams, as well as new entrepreneurs. The firm is open to investing in both privately-held and public companies. If a management team is incomplete or inexperienced, The firm is open to working to fill or change the team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.